Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

Writing Strong Antibody Claims: Avoiding or Addressing USPTO Rejections for Written Description and Enablement

By Ryan P. Hiler and Jessamine Pilcher
March 31, 2025

Many patent applicants currently face difficulty in obtaining antibody claims because of written description and enablement rejections under 35 U.S.C. §112(a). The United States Patent & Trademark Office (USPTO) routinely rejects claims as too broad, arguing that such claims cover more antibodies than the specification discloses, or that undue experimentation would be needed to determine whether an antibody reads on the claims. These heightened disclosure requirements increase laboratory costs to generate sufficient data for a §112(a)-proof specification.

Written Description and Enablement Generally

The legal standards for written description and enablement are well-established. To meet the written description requirement, the specification must convey with reasonable clarity that as of the filing date the inventor was in possession of the claimed invention. See, Vas-Cath, Inc. v. Mahurkar, 935 F.2d 1555, 1560 (Fed. Cir. 1991); Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. Cir. 2010) (en banc) (specification must “clearly allow persons of ordinary skill in the art to recognize that [the inventor] invented what is claimed.”). The enablement requirement is met if the specification would allow a person of ordinary skill in the art to make and use the claimed invention without undue experimentation. See, Amgen, Inc. v. Sanofi, 598 U.S. 594, 611 (2023).
The Supreme Court observed in Amgen that “[d]espite recent advances, aspects of antibody science remain unpredictable … [and] scientists understand that changing even one amino acid in the sequence can alter an antibody’s structure and function” in unpredictable ways. Amgen, 598 U.S. at 612-13. In Ariad, the Federal Circuit found that the disclosure of three types of molecules supporting the claimed substance for interfering with a gene transcription factor was insufficient to meet the written description requirement. Ariad, 598 F.3d at 1355-58. In Amgen, the Supreme Court held that a claim to antibodies for treating high cholesterol was not adequately enabled even though the specification disclosed multiple embodiments including 26 different antibodies identified by their amino acid sequences. Amgen, 598 U.S. at 612.
Below are best practices for drafting antibody claims and specifications.

This premium content is locked for Entertainment Law & Finance subscribers only

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts

For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473

Read These Next
Bankruptcy Sales: Finding a Diamond In the Rough Image

There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.

Judge Rules Shaquille O'Neal Will Face Securities Lawsuit for Promotion, Sale of NFTs Image

A federal district court in Miami, FL, has ruled that former National Basketball Association star Shaquille O'Neal will have to face a lawsuit over his promotion of unregistered securities in the form of cryptocurrency tokens and that he was a "seller" of these unregistered securities.

Why So Many Great Lawyers Stink at Business Development and What Law Firms Are Doing About It Image

Why is it that those who are best skilled at advocating for others are ill-equipped at advocating for their own skills and what to do about it?

Blockchain Domains: New Developments for Brand Owners Image

Blockchain domain names offer decentralized alternatives to traditional DNS-based domain names, promising enhanced security, privacy and censorship resistance. However, these benefits come with significant challenges, particularly for brand owners seeking to protect their trademarks in these new digital spaces.

Coverage Issues Stemming from Dry Cleaner Contamination Suits Image

In recent years, there has been a growing number of dry cleaners claiming to be "organic," "green," or "eco-friendly." While that may be true with respect to some, many dry cleaners continue to use a cleaning method involving the use of a solvent called perchloroethylene, commonly known as perc. And, there seems to be an increasing number of lawsuits stemming from environmental problems associated with historic dry cleaning operations utilizing this chemical.